# Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/RGEN/repligen-corporation-to-present-at-j-p-morgan-2026-healthcare-conference-053249e7
Ticker: RGEN
Company: Repligen
Source: Repligen
Published: 2025-12-18 12:30 EST
## Summary

Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology...

## Article Body
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the J.P. Morgan 2026 Healthcare Conference, being held January 12 – 15 in San Francisco. Olivier Loeillot, President and Chief Executive Officer, will present an overview of the company on Tuesday, January 13 at 2:15 p.m. PT.

A live webcast of the conference presentations will be accessible through Repligen’s Investor Relations website at www.repligen.com , and will be available for replay for a limited period of time following the event.

About Repligen Corporation Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve, primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website at www.repligen.com , and follow us on LinkedIn .

Repligen Contact: Jacob Johnson VP, Investor Relations 781-419-0204 investors@repligen.com
## Recent Company News
- 2026-07-28 11:00 EST — [Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance](https://biopharmsignal.com/news/RGEN/repligen-reports-second-quarter-2026-financial-results-and-updates-full-year-202-465808e8) — Source: Repligen
- 2026-07-22 10:00 EST — [Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media](https://biopharmsignal.com/news/RGEN/repligen-to-acquire-biolife-solutions-expanding-its-cell-therapy-capabilities-wi-b25607c1) — Source: Repligen
- 2026-07-15 11:30 EST — [Repligen to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RGEN/repligen-to-report-second-quarter-2026-financial-results-f6af0b9d) — Source: Repligen
- 2026-05-22 11:30 EST — [Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference](https://biopharmsignal.com/news/RGEN/repligen-corporation-to-present-at-william-blair-46th-annual-growth-stock-confer-369a40b0) — Source: Repligen
- 2026-05-20 11:30 EST — [Repligen Announces Publication of the Company’s 2025 Corporate Sustainability Report](https://biopharmsignal.com/news/RGEN/repligen-announces-publication-of-the-company-s-2025-corporate-sustainability-re-9ff9ce31) — Source: Repligen
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)